NASDAQ:LEGN

Legend Biotech Competitors

$28.45

-1.86 (-6.14 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$28.27

Now: $28.45▼

$30.30

50-Day Range

$23.55

MA: $27.03▼

$30.31

52-Week Range

$23.41

Now: $28.45▼

$43.24

Volume306,709 shs

Average Volume378,382 shs

Market Capitalization$3.76 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Legend Biotech (NASDAQ:LEGN) Vs. ELAN, BMRN, GRFS, TEVA, ZLAB, and BHC

Should you be buying LEGN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Legend Biotech, including Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Zai Lab (ZLAB), and Bausch Health Companies (BHC).

Legend Biotech vs. Elanco Animal Health Stock

Elanco Animal Health (NYSE:ELAN) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares Elanco Animal Health and Legend Biotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$3.07 billion	4.58	$67.90 million	$1.06	28.07
Legend Biotech	$64.39 million	58.33	$-132,970,000.00	N/A	N/A

Elanco Animal Health has higher revenue and earnings than Legend Biotech.

Profitability

This table compares Elanco Animal Health and Legend Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-8.45%	3.43%	2.04%
Legend Biotech	-543.73%	-205.60%	-43.03%

Analyst Ratings

This is a summary of recent recommendations for Elanco Animal Health and Legend Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	2	3	6	0	2.36
Legend Biotech	0	0	3	0	3.00

Elanco Animal Health currently has a consensus target price of $31.35, suggesting a potential upside of 5.38%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than Elanco Animal Health.

Institutional & Insider Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Elanco Animal Health beats Legend Biotech on 8 of the 11 factors compared between the two stocks.

Legend Biotech vs. BioMarin Pharmaceutical Stock

BioMarin Pharmaceutical (NASDAQ:BMRN) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares BioMarin Pharmaceutical and Legend Biotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$1.70 billion	8.22	$-23,850,000.00	$0.07	1,101.00
Legend Biotech	$64.39 million	58.33	$-132,970,000.00	N/A	N/A

BioMarin Pharmaceutical has higher revenue and earnings than Legend Biotech.

Profitability

This table compares BioMarin Pharmaceutical and Legend Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	45.74%	4.34%	2.84%
Legend Biotech	-543.73%	-205.60%	-43.03%

Analyst Ratings

This is a summary of recent recommendations for BioMarin Pharmaceutical and Legend Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0	8	11	0	2.58
Legend Biotech	0	0	3	0	3.00

BioMarin Pharmaceutical currently has a consensus target price of $117.50, suggesting a potential upside of 52.46%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than BioMarin Pharmaceutical.

Institutional & Insider Ownership

97.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats Legend Biotech on 8 of the 11 factors compared between the two stocks.

Legend Biotech vs. Grifols Stock

Grifols (NASDAQ:GRFS) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Grifols and Legend Biotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$5.71 billion	2.17	$700.16 million	$1.17	15.38
Legend Biotech	$64.39 million	58.33	$-132,970,000.00	N/A	N/A

Grifols has higher revenue and earnings than Legend Biotech.

Profitability

This table compares Grifols and Legend Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grifols	12.79%	10.65%	4.79%
Legend Biotech	-543.73%	-205.60%	-43.03%

Analyst Recommendations

This is a summary of recent ratings for Grifols and Legend Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	0	2	5	0	2.71
Legend Biotech	0	0	3	0	3.00

Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Grifols.

Institutional and Insider Ownership

15.2% of Grifols shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Grifols beats Legend Biotech on 6 of the 10 factors compared between the two stocks.

Legend Biotech vs. Teva Pharmaceutical Industries Stock

Teva Pharmaceutical Industries (NYSE:TEVA) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Teva Pharmaceutical Industries and Legend Biotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$16.89 billion	0.71	$-998,000,000.00	$2.31	4.78
Legend Biotech	$64.39 million	58.33	$-132,970,000.00	N/A	N/A

Legend Biotech has lower revenue, but higher earnings than Teva Pharmaceutical Industries.

Profitability

This table compares Teva Pharmaceutical Industries and Legend Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	-24.17%	19.32%	4.89%
Legend Biotech	-543.73%	-205.60%	-43.03%

Analyst Recommendations

This is a summary of recent ratings for Teva Pharmaceutical Industries and Legend Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1	9	4	0	2.21
Legend Biotech	0	0	3	0	3.00

Teva Pharmaceutical Industries presently has a consensus target price of $11.80, suggesting a potential upside of 6.88%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Teva Pharmaceutical Industries.

Institutional and Insider Ownership

51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Teva Pharmaceutical Industries beats Legend Biotech on 7 of the 11 factors compared between the two stocks.

Legend Biotech vs. Zai Lab Stock

Zai Lab (NASDAQ:ZLAB) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Zai Lab and Legend Biotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$12.98 million	905.24	$-195,070,000.00	($3.03)	-43.77
Legend Biotech	$64.39 million	58.33	$-132,970,000.00	N/A	N/A

Legend Biotech has higher revenue and earnings than Zai Lab.

Profitability

This table compares Zai Lab and Legend Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zai Lab	N/A	N/A	N/A
Legend Biotech	-543.73%	-205.60%	-43.03%

Analyst Recommendations

This is a summary of recent ratings for Zai Lab and Legend Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	0	0	5	0	3.00
Legend Biotech	0	0	3	0	3.00

Zai Lab presently has a consensus target price of $159.00, suggesting a potential upside of 19.88%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Zai Lab.

Institutional and Insider Ownership

81.3% of Zai Lab shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Zai Lab beats Legend Biotech on 6 of the 9 factors compared between the two stocks.

Legend Biotech vs. Bausch Health Companies Stock

Bausch Health Companies (NYSE:BHC) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

This table compares Bausch Health Companies and Legend Biotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	$8.60 billion	1.27	$-1,788,000,000.00	$4.43	6.95
Legend Biotech	$64.39 million	58.33	$-132,970,000.00	N/A	N/A

Legend Biotech has lower revenue, but higher earnings than Bausch Health Companies.

Profitability

This table compares Bausch Health Companies and Legend Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-23.92%	173.20%	4.21%
Legend Biotech	-543.73%	-205.60%	-43.03%

Analyst Recommendations

This is a summary of recent ratings for Bausch Health Companies and Legend Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	1	4	7	0	2.50
Legend Biotech	0	0	3	0	3.00

Bausch Health Companies presently has a consensus target price of $32.5833, suggesting a potential upside of 5.86%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 78.09%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Bausch Health Companies.

Institutional and Insider Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. Comparatively, 18.9% of Legend Biotech shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bausch Health Companies beats Legend Biotech on 7 of the 11 factors compared between the two stocks.